Skip to Content

'
Herbert B. Grossman, MD

Present Title & Affiliation

Primary Appointment

W.A. "Tex" and Deborah Moncrief, Jr., Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1970 Temple University, Philadelphia, PA, MD, Medicine
1966 La Salle College, Philadelphia, PA, BA, Biology

Postgraduate Training

1/1978-1980 Research and Clinical Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY
1/1974-1977 Urology Residency, University of Michigan Medical Center, Ann Arbor, MI
1/1973-1974 General Surgical Residency, St. Joseph Mercy Hospital, Ann Arbor, MI
1/1970-1971 Straight Surgical Internship, University of Michigan Medical Center, Ann Arbor, MI

Board Certifications

2/1979 American Board of Urology

Experience/Service

Academic Appointments

Professor, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1998-present

Honors and Awards

2004 Pfizer/AUA Visiting Professorship in Urology
2002 President's Award for Scientific Excellence, First Prize Poster Presentation, International Society for Preventive Oncology
2000-present Who's Who in America
1999-2008 Best Doctors in America, Editions
1995 Faculty Excellence Award, The University of Texas M. D. Anderson Cancer Center
1994-present W. A. "Tex" and Deborah Moncrief, Jr. Distinguished Chair in Urology, The University of Texas M. D. Anderson Cancer Center
1990 Silver Cystoscope Award, Annual Award from the Senior Urology Residents for Excellence in Teaching
1980 Second Prize, Ferdinand C. Valentine Urology Prize Essay Contest
1979-1980 Clinical Fellow, American Cancer Society
1979 Ferdinand C. Valentine Fellow, Section on Urology, New York Academy of Medicine
1977 First Prize, Detroit Branch, American Urological Association Resident Essay Competition
1976 Second Prize, Detroit Branch, American Urological Association Resident Essay Competition
1975 Fifth Prize, Detroit Branch, American Urological Association Resident Essay Competition

Selected Publications

Peer-Reviewed Original Research Articles
1. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. J Clin Oncol. e-Pub 5/2009. PMID: 19414678.
2. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-152, 1/2009. e-Pub 10/2008. PMID: 18848348.
3. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 100(19). e-Pub 9/23/2008. PMID: 18812553.
4. Liang D, Lin J, Grossman HB, Ma J, Wei B, Dinney CP, Wu X. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control, May-Jun, 5/14/2008. PMID: 18478342.
5. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol, May-Jun, 5/14/2008. PMID: 18485384.
6. Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest, May-Jun, 5/2008. PMID: 18458673.
7. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 68(7):2530-7, 4/1/2008. PMID: 18381463.
8. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236-44, 4/1/2008. PMID: 18381966.
9. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112(11):2467-2474, 3/24/2008. PMID: 18361427.
10. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519-25, 3/2008. PMID: 18342201.
11. Harris LD, La Cerda JD, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog, 2/20/2008. PMID: 18288642.
12. Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP, Wu X, Gu J. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 7(2):141-8, 2/1/2008. e-Pub 2008. PMID: 17923445.
13. Gee J, Lee IL, Grossman HB, Sabichi AL. Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. Urol Oncol, 1/7/2008. PMID: 18367112.
14. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 14(1):224-9, 1/1/2008. PMID: 18172274.
15. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol 10(4):281-9, 2008. PMCID: PMC2615101.
16. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. J Clin Oncol 26(1):121-126, 2008. PMID: 18165646.
17. Fradet Y. Grossman HB. Gomella L. Lerner S. Cookson M. Albala D. Droller MJ. PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. Journal of Urology 178:68-73, 2007.
18. Grossman HB. Gomella L. Fradet Y. Morales A. Presti J. Ritenour C. Nseyo U. Droller MJ. PC B302/01 Study Group. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. Journal of Urology 178:62-67, 2007.
19. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70:252-256, 2007.
20. Zhao H, Lin J, Grossman HB, Hernandez LM, Dinney CP, Wu X. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer 120:2208-2213, 2007.
21. Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A 104:13732-13737, 2007.
22. Grossman B. Genetic polymorphism in bladder Cancer. Front Biosci 12:192-213, 2007.
23. Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, Wu X. Genotypes, haplotypes, and diplotypes of XPC and risk of bladder cancer. Carcinogenesis 28:698-703, 2007. PMID: 17052994.
24. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner S, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28:2160-2165, 2007.
25. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. High-Order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev 16:84-91, 2007.
26. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13:2614-2620, 2007.
27. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110:62-67, 2007.
28. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 70:473-476, 2007.
29. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110:764-769, 2007.
30. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. p0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52:769-776, 2007.
31. Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting individualized probabilities of developing bladder cancer in white individuals. Clin Oncol 25:4974-4981, 2007.
32. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol 38:753-761, 2007.
33. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol 38:753-761, 2007.
34. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25:38-45, 2007.
35. Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18:839-845, 2007.
36. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644-8, 12/2006. PMID: 17178858.
37. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98:1176-80, 12/2006. PMID: 17125474.
38. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep 16:807-10, 10/2006. PMID: 16969498.
39. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68:549-53, 9/2006. PMID: 16979735.
40. Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, Wu X. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet 70:240-5, 9/2006. PMID: 16922727.
41. Lin J, Dinney CP, Grossman HB, Wu X. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev 15:1746-9, 9/2006. PMID: 16985040.
42. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12(15):4671-7, 8/2006. PMID: 16899617.
43. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer, 8/2006. PMID: 16894527.
44. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. Cancer 107(4):705-711, 7/2006. PMID: 16845665.
45. Cardenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 108(1):169-75, 7/2006. PMID: 16816072.
46. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176(1):53-7; discussion 57, 7/2006. PMID: 16753366.
47. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175:2058-62, 6/2006. PMID: 16697803.
48. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78:464-79, 3/2006. PMID: 16465622.
49. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175:1133-7, 3/2006. PMID: 16469639.
50. Grossman HB. Chemoprevention of bladder cancer. Urology 67:19-22; discussion 23-4, 3/2006. PMID: 16530070.
51. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 67:466-71, 3/2006. PMID: 16527559.
52. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175:881-5, 3/2006. PMID: 16469571.
53. Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS. The use of urine-based biomarkers in bladder cancer. Urology 67:62-4, 3/2006. PMID: 16530080.
54. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67:518-23, 3/2006. PMID: 16527570.
55. Kim MS, Jeong J, Majewski T, Kram A, Yoon DS, Zhang RD, Li JZ, Ptaszynski K, Kuang TC, Zhou JH, Sathyanarayana UG, Tuziak T, Johnston DA, Grossman HB, Gazdar AF, Scherer SE, Benedict WF, Czerniak B. Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab Invest 86:175-90, 2/2006. PMID: 16402033.
56. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15:471-7, 2/2006. PMID: 16391871.
57. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Jama 295(3):299-305, 1/2006. PMID: 16418465.
58. Zou C, Zhou J, Qian L, Feugang JM, Liu J, Wang X, Wu S, Ding H, Zou C, Liebert M, Grossman HB. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells. Front Biosci 11:2007-16, 2006. PMID: 16720286.
59. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl 1):35-63, 12/2005. PMID: 16399415.
60. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, 3rd, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl 1):64-74, 12/2005. PMID: 16399416.
61. Zhao H, Liang D, Grossman HB, Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 66(4):769-74, 10/2005. PMID: 16230136.
62. Gu J, Spitz MR, Zhao H, Lin J, Grossman HB, Dinney CP, Wu X. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis 26(10):1741-7, 10/2005. PMID: 15905204.
63. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer 104(5):975-84, 9/2005. PMID: 16044400.
64. Gu J, Grossman HB, Dinney CP, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 6(6):575-84, 9/2005. PMID: 16142998.
65. Spiess PE, Tuziak T, Kassouf W, Grossman HB, Czerniak B. Malignant mesothelioma of the tunica vaginalis. Urology 66(2):397-401, 8/2005. PMID: 16040098.
66. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746-56, 8/2005. PMID: 16110031.
67. Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, Chenoweth MA, Zhang H, Spitz MR, Wu X. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Cancer 104(1):30-5, 7/2005. PMID: 15912517.
68. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 85(4):532-49, 4/2005. PMID: 15778693.
69. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, Spitz MR, Wu X. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 14(4):878-84, 4/2005. PMID: 15824159.
70. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. Jama 293(7):810-6, 2/2005. PMID: 15713770.
71. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 11(4):1408-15, 2/2005. PMID: 15746040.
72. Goebell PJ, Groshen S, Schmitz-Drager BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res 11(2 Pt 1):413-5, 1/2005. PMID: 15701822.
73. Schabath MB, Spitz MR, Lerner SP, Pillow PC, Hernandez LM, Delclos GL, Grossman HB, Wu X. Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer 53(2):144-51, 2005. PMID: 16573375.
74. Zou C, Ramakumar S, Qian L, Zou C, Zang R, Wang J, Grossman HB, Lotan R, Liebert M. Effect of retinoic acid and interferon alpha-2a on transitional cell carcinoma of bladder. J Urol 173(1):247-51, 2005. PMID: 15592090.
75. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, Spitz MR, Wu X. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 14:878-884, 2005.
76. Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev 29(2):170-4, 2005. PMID: 15829377.
77. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25(6):1631-9, 12/2004. PMID: 15547700.
78. Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, Wu X. Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer 41(4):330-8, 12/2004. PMID: 15390186.
79. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, Wu X. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr 134(12):3362-9, 12/2004. PMID: 15570038.
80. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 64(24):8973-9, 12/2004. PMID: 15604261.
81. Shao L, Lerner SL, Bondaruk J, Czerniak BA, Zeng X, Grossman HB, Spitz MR, Wu X. Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes Cancer 41(4):379-89, 12/2004. PMID: 15390184.
82. Lin J, Spitz MR, Wang Y, Schabath MB, Gorlov IP, Hernandez LM, Pillow PC, Grossman HB, Wu X. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 25(9):1639-47, 9/2004. PMID: 15117811.
83. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481-4, 8/2004. PMID: 15247709.
84. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22(14):2781-9, 7/2004. PMID: 15199091.
85. Dhanani NN, Jones DM, Grossman HB. Medical management of renal actinomycosis. J Urol 171(6 Pt 1):2373-4, 6/2004. PMID: 15126826.
86. Herr HW, Faulkner JR, Grossman HB, Crawford ED. Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer 100(11):2470-5, 6/2004. PMID: 15160354.
87. Zhu Y, Spitz MR, Zhang H, Grossman HB, Frazier ML, Wu X. Methyl-CpG-binding domain 2: a protective role in bladder carcinoma. Cancer 100(9):1853-8, 5/2004. PMID: 15112265.
88. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 11(4):273-9, 4/2004. PMID: 14765130.
89. Tanaka M Grossman HB. Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 11(2):537-41, 2/2004. PMID: 14719096.
90. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman HB, Czerniak B, Gazdar AF. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64(4):1425-30, 2/2004. PMID: 14973053.
91. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman HB, Czerniak B, Gazdar AF. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64:1425-1430, 2004.
92. Goebell PJ, Groshen S, Schmitz-Drager BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Waldman F, Cote RJ. The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol 22:277-284, 2004.
93. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett 202(1):61-9, 12/2003. PMID: 14643027.
94. Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 106(5):661-5, 9/2003. PMID: 12866024.
95. Tanaka M Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 10(19):1636-42, 9/2003. PMID: 12923562.
96. Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, Grossman HB. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol 170(3):975-8, 9/2003. PMID: 12913753.
97. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859-66, 8/2003. PMID: 12944571.
98. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 21(4):266-70, 7/2003. PMID: 12954496.
99. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
100. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 21(12):2247-53, 6/2003. PMID: 12805322.
101. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 536(1-2):131-7, 4/2003. PMID: 12694753.
102. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 95(7):540-7, 4/2003. PMID: 12671022.
103. Gee J, Tanaka M, Grossman HB. Connexin 26 is abnormally expressed in bladder cancer. J Urol 169(3):1135-7, 3/2003. PMID: 12576868.
104. Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X. Death receptor 4 and bladder cancer risk. Cancer Res 63(6):1157-9, 3/2003. PMID: 12649168.
105. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169(2):714-7, 2/2003. PMID: 12544349.
106. 155. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett 202:61-69, 2003.
107. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz, MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95:1211-1218, 2003.
108. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94(17):1320-9, 9/2002. PMID: 12208897.
109. Sawczuk IS, Pickens CL, Vasa UR, Ralph DA, Norris KA, Miller MC, Ng AY, Grossman HB, Veltri RW. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 7(5):185-90, 9/2002. PMID: 12644214.
110. Zou C, Guan Y, Zou C, Wang J, Wang LE, Liebert M, Grossman HB, Wei Q. N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines. Cancer Lett 180(2):131-7, 6/2002. PMID: 12175543.
111. Tanaka M Grossman HB. Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 12(18):2225-36, 12/2001. PMID: 11779406.
112. Yang WH, Liebert M, Price RE, Cromeens DM, Lin JS, Grossman HB. Extravesical cryosurgical approach for VX2 bladder tumor in rabbits. Urol Res 29(5):345-9, 10/2001. PMID: 11762797.
113. Yoon DS, Li L, Zhang RD, Kram A, Ro JY, Johnston D, Grossman HB, Scherer S, Czerniak B. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene 20(36):5005-14, 8/2001. PMID: 11526485.
114. Kram A, Li L, Zhang RD, Yoon DS, Ro JY, Johnston D, Grossman HB, Scherer S, Czerniak B. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest 81(7):1039-48, 7/2001. PMID: 11454992.
115. Lance RS, Dinney CP, Swanson D, Babaian RJ, Pisters LL, Palmer LJ, Grossman HB. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep 8(4):723-6, 7/2001. PMID: 11410772.
116. Zou C, Liebert M, Zou C, Grossman HB, Lotan R. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J Urol 165(3):986-92, 3/2001. PMID: 11176527.
117. Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, Jones J, Balcerzak SP, Crawford ED, Grossman HB. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 165(1):56-60; discussion 60-1, 2001. PMID: 11125363.
118. Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, Grossman HB. Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther 8(2):139-48, 2001. PMID: 11313783.
119. Tanaka M, Grossman HB. Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with cisplatin. Hum Gene Ther 12:2225-2236, 2001.
120. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 8(1):9-15, 2001. PMID: 11115562.
121. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7(12):1575-80, 12/2000. PMID: 11228536.
122. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19(47):5406-12, 11/2000. PMID: 11103942.
123. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 6(5):1854-64, 5/2000. PMID: 10815908.
124. deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Jr, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol 37(5):595-600, 5/2000. PMID: 10765099.
125. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124-9, 4/2000. PMID: 10737480.
126. Marchetti A, Wang L, Magar R, Grossman HB, Lamm DL, Schellhammer PF, Erwin-Toth P. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 22(4):422-38, 4/2000. PMID: 10823364.
127. Grossman HB, Lee C, Bromberg J, Liebert M. Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. Oncol Rep 7(1):13-6, 2000. PMID: 10601583.
128. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 162(3 Pt 1):710-4, 9/1999. PMID: 10458349.
129. Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB, Fritsche HA, Jr. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 20(5):285-90, 5/1999. PMID: 10319229.
130. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 211(1):249-56, 4/1999. PMID: 10189480.
131. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185-96, 2/1999. PMID: 10022124.
132. Zou C, Wang L, Liebert M, Grossman HB, Lotan R, Wei Q. Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. Int J Oncol 13(5):1037-41, 11/1998. PMID: 9772297.
133. Dinney CP, Babkowski RC, Antelo M, Perrotte P, Liebert M, Zhang HZ, Palmer J, Veltri RW, Katz RL, Grossman HB. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 160(4):1285-90, 10/1998. PMID: 9751337.
134. Lianes P, Charytonowicz E, Cordon-Cardo C, Fradet Y, Grossman HB, Hemstreet GP, Waldman FM, Chew K, Wheeless LL, Faraggi D. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res 4(5):1267-71, 5/1998. PMID: 9607586.
135. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4(4):829-34, 4/1998. PMID: 9563875.
136. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159(2):394-8, 2/1998. PMID: 9649246.
137. Kagan J, Liu JH, Stein JD, Wagner SS, Babkowsk R, Grossman BH, Katz RL. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 16:909-913, 1998.
138. Grossman HB, Debruyne FMJ, Akaza, H, Aso, Y, Kagawa, S, Kakehi, Y, van der Meijden APM, Ratliff, TL. Committee 10. New treatment approaches for superficial and invasive bladder cancer. Urol Oncol 4:183-187, 1998.
139. Kaufman AM, Slaton JW, Czerniak BA, Grossman HB. Transitional cell carcinoma of the bladder with involvement of vasa deferentia. J Urol 159(1):204-5, 1998. PMID: 9400477.
140. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MG, Jr, Silberman SR, Butman BT. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 158(3 Pt 1):801-5, 9/1997. PMID: 9258086.
141. Slaton JW, Dinney CP, Veltri RW, Miller CM, Liebert M, O'Dowd GJ, Grossman HB. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 158(3 Pt 1):806-11, 9/1997. PMID: 9258087.
142. Kosuda S, Wahl RL, Grossman HB. Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET. Ann Nucl Med 11(3):263-6, 8/1997. PMID: 9310177.
143. Kosuda S, Fisher S, Kison PV, Wahl RL, Grossman HB. Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 11(3):195-9, 8/1997. PMID: 9310167.
144. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24(6):615-20, 6/1997. PMID: 9169567.
145. Reeder JE, Cox C, Wheeless LL, Flint A, Liebert M, Grossman HB. Variability of DNA analysis by image cytometry. Bladder Tumor Marker Network. Cytometry 28(2):176-80, 6/1997. PMID: 9181309.
146. Smith JA, Jr, Crawford ED, Paradelo JC, Blumenstein B, Herschman BR, Grossman HB, Christie DW. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 157(3):805-7; discussion 807-8, 3/1997. PMID: 9072571.
147. Liebert M, Hubbel A, Chung M, Wedemeyer G, Lomax MI, Hegeman A, Yuan TY, Brozovich M, Wheelock MJ, Grossman HB. Expression of mal is associated with urothelial differentiation in vitro: identification by differential display reverse-transcriptase polymerase chain reaction. Differentiation 61(3):177-85, 2/1997. PMID: 9084136.
148. Kim SY, Bachman NJ, Nair TS, Goldsmith S, Liebert M, Grossman HB, Lomax MI, Carey TE. Beta 4 integrin transfection of UM-UC-2 (human bladder carcinoma) cells: stable expression of a spontaneous cytoplasmic truncation mutant with rapid loss of clones expressing intact beta 4. Cancer Res 57(1):38-42, 1997. PMID: 8988037.
149. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 37(1):41-9, 1997. PMID: 9054875.
150. Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL, Hemstreet GP, 3rd. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Cancer Epidemiol Biomarkers Prev 5(12):971-8, 12/1996. PMID: 8959319.
151. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD, Jr, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Morganroth J. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 48(1):21-7, 7/1996. PMID: 8693646.
152. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199(3):751-6, 6/1996. PMID: 8638000.
153. Fukunaga-Johnson N, Lee SW, Liebert M, Grossman HB. Molecular analysis of a gene, BB1, overexpressed in bladder and breast carcinoma. Anticancer Res 16(3A):1085-90, 5/1996. PMID: 8702217.
154. Wideroff L, Schottenfeld D, Carey TE, Beals T, Fu G, Sakr W, Sarkar F, Schork A, Grossman HB, Shaw MW. Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 28(2):117-23, 2/1996. PMID: 8604392.
155. Hemstreet GP, 3rd, Rao J, Hurst RE, Bonner RB, Waliszewski P, Grossman HB, Liebert M, Bane BL. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. J Cell Biochem Suppl 25:197-204, 1996. PMID: 9027619.
156. deVere White RW, Deitch AD, Tesluk H, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. Prognostic significance of DNA ploidy in Ta/T1 bladder cancer. A Southwest Oncology Group Study. Urol Oncol 2:27-34, 1996.
157. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154(6):2059-63; discussion 2063-4, 12/1995. PMID: 7500458.
158. Rozanski TA, Grossman HB. Renal cell carcinoma in a patient with mesenteric lipodystrophy. J Urol 153(6):1893-4, 6/1995. PMID: 7752343.
159. Kakizoe T, Fair WR, Smith PH, Algaba F, Ferrari P, Grossman HB, Zirkali Z, Tsukamoto T, Tachibana M. What is the biology of invasion and metastasis in bladder cancer? Int J Urol 2 Suppl 2:58-63, 6/1995. PMID: 7553306.
160. Flint A, Grossman HB, Liebert M, Lloyd RV, Bromberg J. DNA and PCNA content of renal cell carcinoma and prognosis. Am J Clin Pathol 103(1):14-9, 1995. PMID: 7817936.
161. Schwartz SL, Swierzewski SJ, 3rd, Sondak VK, Grossman HB. Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol 153(1):154-7, 1995. PMID: 7966755.
162. Podolski J, Hadaczek P, Gibas Z, Gibas L, Grossman HB, Limon J, Huebner K, Lubinski J. Non-isotopic procedure with silver staining of polyacrylamide gels in detection of genomic abnormalities in tumors using microsatellites. Folia Histochem Cytobiol 33(2):117-23, 1995. PMID: 8617377.
163. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA Jr, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Grossman HB. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group study. Urol Oncol 1:119-126, 1995.
164. Kennelly MJ, Grossman HB, Cho KJ. Outcome analysis of 42 cases of renal angiomyolipoma. J Urol 152(6 Pt 1):1988-91, 12/1994. PMID: 7966657.
165. Rozanski TA, Grossman HB. Recent developments in the pathophysiology of bladder cancer. AJR Am J Roentgenol 163(4):789-92, 10/1994. PMID: 8092012.
166. Grossman HB, Sommerfield D, Konnak JW, Bromberg J. Long-term assessment of renal function following nephrectomy for stage I renal carcinoma. Br J Urol 74(3):279-82, 9/1994. PMID: 7953254.
167. Grossman HB, Liebert M, Lee IW, Lee SW. Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer Res 54(11):3062-5, 6/1994. PMID: 8187096.
168. Liebert M, Washington R, Stein J, Wedemeyer G, Grossman HB. Expression of the VLA beta 1 integrin family in bladder cancer. Am J Pathol 144(5):1016-22, 5/1994. PMID: 8178925.
169. Liebert M, Washington R, Wedemeyer G, Carey TE, Grossman HB. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Am J Pathol 144(4):787-95, 4/1994. PMID: 7512792.
170. Swierzewski SJ, 3rd, Flood HD, Grossman HB. Acquired crossed renal ectopia secondary to a giant renal cyst. Urology 43(3):382-5, 3/1994. PMID: 8134995.
171. Shinohara N, Nonomura K, Takakura F, Hamada M, Grossman HB, Koyanagi T. Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract. Eur Urol 26(4):327-33, 1994. PMID: 7713132.
172. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan DR, Florence C, Pozzatti R, McClellan M, Walther M, Bander NH, Grossman HB, Brauch H, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nature Genetics 7:85-90, 1994.
173. Park J, Shinohara N, Liebert M, Noto L, Flint A, Grossman HB. P-glycoprotein expression in bladder cancer. J Urol 151(1):43-6, 1994. PMID: 7902877.
174. Sandler HM, Bree RL, McLaughlin PW, Grossman HB, Lichter AS. Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys 27(4):915-9, 11/1993. PMID: 8244823.
175. Summers RM, Korobkin M, Quint LE, Ellis JH, Grossman HB, Sandler HM, Mandell SH. Pelvic CT findings after radical prostatectomy. J Comput Assist Tomogr 17(5):767-71, 9/1993. PMID: 8370832.
176. Shinohara N, Liebert M, Wedemeyer G, Chang JH, Grossman HB. Evaluation of multiple drug resistance in human bladder cancer cell lines. J Urol 150(2 Pt 1):505-9, 8/1993. PMID: 8100862.
177. Grossman HB. Bladder contracture following intravesical BCG immunotherapy. Urology 41(4):353-5, 4/1993. PMID: 8470323.
178. Liebert M, Wedemeyer G, Stein JA, Washington R, Jr, Faerber G, Flint A, Grossman HB. Evidence for urothelial cell activation in interstitial cystitis. J Urol 149(3):470-5, 3/1993. PMID: 8094760.
179. Grossman HB, Sandler HM, Perez-Tamayo C. Treatment of T3a bladder cancer with iridium implantation. Urology 41(3):217-20, 3/1993. PMID: 8442300.
180. Liebert M, Wedemeyer G, Stein JA, Washington RW, Jr, Van Waes C, Carey TE, Grossman HB. The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer. Hybridoma 12(1):67-80, 2/1993. PMID: 8454305.
181. Carey TE, Nair TS, Chern C, Liebert M, Grossman HB, Wolf GT, Van Waes C. Blood group antigens and integrins as biomarkers in head and neck cancer: is aberrant tyrosine phosphorylation the cause of altered alpha 6 beta 4 integrin expression? J Cell Biochem Suppl 17F:223-32, 1993. PMID: 8412198.
182. Zaragoza MR, Grossman HB. Objective treatment response to endocrine therapy in metastatic prostate cancer. Urology 40(5):405-8, 11/1992. PMID: 1441036.
183. Grossman HB, Schwartz SL, Konnak JW. Ureteroscopic treatment of urothelial carcinoma of the ureter and renal pelvis. J Urol 148(2 Pt 1):275-7, 8/1992. PMID: 1635116.
184. Meyers FJ, Blumenstein B, Crawford ED, Hynes HE, Montie JE, Taylor SA, Grossman HB, Natale RB. Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. J Urol 148(1):52-4, 7/1992. PMID: 1613880.
185. Abruzzo LV, Thornton AJ, Liebert M, Grossman HB, Evanoff H, Westwick J, Strieter RM, Kunkel SL. Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. Am J Pathol 140(2):365-73, 2/1992. PMID: 1739130.
186. Grossman HB, Washington RW, Jr, Carey TE, Liebert M. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl 16I:63-8, 1992. PMID: 1305690.
187. Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 146(6):1631-6, 12/1991. PMID: 1719252.
188. Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 146(6):1470-4, 12/1991. PMID: 1942320.
189. Ellis JH, McCullough NB, Francis IR, Grossman HB, Platt JF. Transitional cell carcinoma of the bladder: patterns of recurrence after cystectomy as determined by CT. AJR Am J Roentgenol 157(5):999-1002, 11/1991. PMID: 1927826.
190. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Jr, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325(17):1205-9, 10/1991. PMID: 1922207.
191. Sklar MD, Thompson E, Welsh MJ, Liebert M, Harney J, Grossman HB, Smith M, Prochownik EV. Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol 11(7):3699-710, 7/1991. PMID: 2046673.
192. Harney JV, Liebert M, Wedemeyer G, Washington R, Stein J, Buchsbaum D, Steplewski Z, Grossman HB. The expression of epidermal growth factor receptor on human bladder cancer: potential use in radioimmunoscintigraphy. J Urol 146(1):227-31, 7/1991. PMID: 2056595.
193. Quint LE, Van Erp JS, Bland PH, Del Buono EA, Mandell SH, Grossman HB, Gikas PW. Prostate cancer: correlation of MR images with tissue optical density at pathologic examination. Radiology 179(3):837-42, 6/1991. PMID: 2028002.
194. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67(6):1544-50, 3/1991. PMID: 2001543.
195. Quint LE, Van Erp JS, Bland PH, Mandell SH, Del Buono EA, Grossman HB, Glazer GM, Gikas PW. Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. AJR Am J Roentgenol 156(3):511-6, 3/1991. PMID: 1899746.
196. Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, Grossman HB. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 145(2):279-83, 2/1991. PMID: 1988718.
197. Feng MR, Liebert M, Wedemeyer G, Grossman HB, Mancini WR, Williams M, Wagner JG. Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells. Sel Cancer Ther 7(2):75-83, 1991. PMID: 1754730.
198. Usansky JI, Liebert M, Wedemeyer G, Grossman HB, Wagner JG. The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline. Sel Cancer Ther 7(4):139-50, 1991. PMID: 1822001.
199. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 144(6):1328-30, 12/1990. PMID: 2231917.
200. Ward E, Halperin W, Thun M, Grossman HB, Fink B, Koss L, Osorio AM, Schulte P. Screening workers exposed to 4,4'-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy. J Occup Med 32(9):865-8, 9/1990. PMID: 2074509.
201. Key DW, Moyad R, Grossman HB. Seminoma associated with crossed fused renal ectopia. J Urol 143(5):1015-6, 5/1990. PMID: 2329590.
202. Grainger R, Gikas PW, Grossman HB. Urothelial carcinoma occurring within an inverted papilloma of the ureter. J Urol 143(4):802-4, 4/1990. PMID: 2313813.
203. Grossman HB, Liebert M, Wedemeyer G, Wilson G, Flint A. Fibronectin distribution in normal and malignant urothelium. J Urol 143(2):418-20, 2/1990. PMID: 2405193.
204. Liebert M, Wedemeyer G, Chang JHC, Stein JA, McKeever PE, Carey TE, Flint A, Steplewski Z, Buchsbaum DJ, Wahl RL, Grossman HB. Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. J Urol 144:1288-1292, 1990.
205. Liebert M, Wedemeyer GA, Stein JA, Washington RW, Jr, Flint A, Ren LQ, Grossman HB. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells. Cancer Res 49(23):6720-6, 12/1989. PMID: 2479470.
206. Kozminski M, Konnak JW, Grossman HB. Management of rectal injuries during radical cystectomy. J Urol 142(5):1204-5, 11/1989. PMID: 2810493.
207. Chancellor M, Grossman HB, Konnak J, Diokno AC, Gonzalez J, Pontes JE, Huben RP, King GW. Biocarbon ureterostomy device for urinary diversion. Multicenter clinical trial. Urology 34(1):18-21, 7/1989. PMID: 2665285.
208. Wan J, Grossman HB. Bladder carcinoma in patients age 40 years old or less. Cancer 64:178-81, 7/1989. PMID: 2731112.
209. Chancellor MB, Konnak JW, Grossman HB. Diagnostic value of routine bone scintigraphy renal imaging in renal cell carcinoma. Urology 33(5):440-2, 5/1989. PMID: 2775373.
210. Quint LE, Glazer GM, Chenevert TL, Fechner KP, Gikas PW, Shireman PK, Grossman HB, Li KC. In vivo and in vitro MR imaging of renal tumors: histopathologic correlation and pulse sequence optimization. Radiology 169(2):359-62, 11/1988. PMID: 3174983.
211. Burks D, Grossman HB. Urethral cyst in a man. J Urol 140(3):611-2, 9/1988. PMID: 3411685.
212. Khanderia U, Grossman HB. Evaluation of N-acetylneuraminic acid, carcinoembryonic antigen, and alpha-fetoprotein as markers for advanced carcinoma. J Surg Oncol 37(4):264-8, 4/1988. PMID: 2452322.
213. Grossman HB, Konnak JW. Is radical cystectomy indicated in patients with regional lymphatic metastases? Urology 31(3):214-6, 3/1988. PMID: 3347968.
214. Grossman HB, Wedemeyer G, Stein J. Autologous antibodies to human bladder cancer. Cancer Immunol Immunother 26(3):269-72, 1988. PMID: 3383207.
215. Ward E, Halperin W, Thun M, Grossman HB, Fink B, Koss L, Osorio AM, Schulte P. Bladder tumors in two young males occupationally exposed to MBOCA. Am J Ind Med 14(3):267-72, 1988. PMID: 3189344.
216. Amendola BE, Hutchinson R, Grossman HB, Amendola MA. Isolated testicular leukemic relapse. Response to radiation therapy. Urology 30(3):240-3, 9/1987. PMID: 3477044.
217. Wilson GN, Dasouki M, Grossman HB. Cell-specific ribosomal DNA spacer variability in human urothelial carcinoma cultures. J Urol 137(2):324-6, 2/1987. PMID: 2879945.
218. Konchanin RP, Cho KJ, Grossman HB. Preoperative devascularization of advanced renal adenocarcinoma using a sclerosing agent. J Urol 137(2):199-201, 2/1987. PMID: 3806803.
219. Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B. Improved growth of human urothelial carcinoma cell cultures. J Urol 136(4):953-9, 10/1986. PMID: 3761468.
220. Crawford ED, McKenzie D, Mansson W, Totonchy M, Grossman HB, Davis M, Lamm DL, Duchek M. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. J Urol 136(3):668-9, 9/1986. PMID: 3735544.
221. Grossman HB. Diagnosis and treatment of bladder carcinoma. Compr Ther 12(8):42-7, 8/1986. PMID: 3742997.
222. Grossman HB. Complications of 125I implantation: inability to deflate Foley catheter. Urology 28(1):55, 7/1986. PMID: 3727232.
223. Amendola MA, Glazer GM, Grossman HB, Aisen AM, Francis IR. Staging of bladder carcinoma: MRI-CT-surgical correlation. AJR Am J Roentgenol 146(6):1179-83, 6/1986. PMID: 3486561.
224. Grossman HB. Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment? Urology 27(3):199-204, 3/1986. PMID: 3513424.
225. Grossman HB Wedemeyer G. UM-TC-1, A new human testicular carcinoma cell line. Cancer J 1:22-25, 1986.
226. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol 134(6):1094-6, 12/1985. PMID: 4057398.
227. Konnak JW, Grossman HB. Salvage cystectomy following failed definitive radiation therapy for transitional cell carcinoma of bladder. Urology 26(6):550-3, 12/1985. PMID: 3934829.
228. Begun FP, Grossman HB. Comparison of tissue culture cells and histological sections for use in screening monoclonal antibodies. J Urol 134(5):982-4, 11/1985. PMID: 3903221.
229. Gillett W, Grossman HB, Lee R. Visual disturbances in TUR reaction. Urology 25(6):573-5, 6/1985. PMID: 4012948.
230. Grossman HB, Wedemeyer G, Ren LQ. Human renal carcinoma: characterization of five new cell lines. J Surg Oncol 28(3):237-44, 3/1985. PMID: 4038766.
231. Gottesman JE, Crawford ED, Grossman HB, Scardino P, McCracken JD. Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study. Urology 25(3):248-50, 3/1985. PMID: 3156442.
232. Gross MD, Skinner RW, Grossman HB. Radioimmunodetection of a transplantable human bladder carcinoma in a nude mouse. Invest Radiol 19(6):530-4, 11/1984. PMID: 6511260.
233. Grossman HB, Sonda LP, 3rd, Lloyd RV, Gikas PW. Carcinosarcoma of bladder. Evaluation by electron microscopy and immunohistochemistry. Urology 24(4):387-9, 10/1984. PMID: 6385441.
234. Grossman HB, Wedemeyer G, Ren L. UM-UC-1 and UM-UC-2: characterization of two new human transitional cell carcinoma lines. J Urol 132(4):834-7, 10/1984. PMID: 6471236.
235. Grossman HB, Wedemeyer G, Ren L, Carey TE. UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. Cancer Res 44(9):4111-7, 9/1984. PMID: 6378378.
236. Begun FP, Grossman HB, Diokno AC, Sogani PC. Malignant melanoma of the penis and male urethra. J Urol 132(1):123-5, 7/1984. PMID: 6726939.
237. Sonda LP, Grossman HB, MacGregor RJ, Gikas PW. Incidental adenocarcinoma of the prostate: the role of repeat transurethral resection in staging. Prostate 5(2):141-6, 1984. PMID: 6709517.
238. Grossman HB. Hybridoma antibodies reactive with human bladder carcinoma cell surface antigens. J Urol 130(3):610-4, 9/1983. PMID: 6887389.
239. Khanderia U, Keller JH, Grossman HB. Serum sialic acid is a biologic marker for malignant disease. J Surg Oncol 23(3):163-6, 7/1983. PMID: 6865437.
240. Grossman HB, Batata M, Hilaris B, Whitmore WF, Jr. 125I implantation for carcinoma of prostate. Further follow-up of first 100 cases. Urology 20(6):591-8, 12/1982. PMID: 7179624.
241. Grossman HB, Kleinert EL, Herr HW, Whitmore WF, Jr. Effects of estrogen administration on serum testosterone in Copenhagen rats. Prostate 3(3):225-9, 1982. PMID: 7100003.
242. Grossman HB. Natural antibody to a human bladder carcinoma cell line. Cancer Immunol Immunother 13(2):89-92, 1982. PMID: 7159876.
243. Grossman HB, Sonda LP, 3rd, Lesser ML. The effect of single dose N-methyl-N-nitrosourea on bladder carcinogenesis by N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide in rats. Invest Urol 18(8):457-9, 5/1981. PMID: 7228579.
244. Grossman HB, Sogani PC. Basal cell carcinoma of scrotum. Urology 17(3):241-2, 3/1981. PMID: 7210374.
245. Grossman HB, Kleinert EL, Lesser ML, Herr HW, Whitmore WF, Jr. Androgen stimulated chemotherapy in the Dunning R-3327 prostatic adenocarcinoma. Urol Res 9(5):237-40, 1981. PMID: 7303347.
246. Montealegre A, Grossman HB. Acute ureteral obstruction from buckshot. Urology 15(2):159-60, 2/1980. PMID: 7355539.
247. Grossman HB. Current therapy of bladder carcinoma. J Urol 121(1):1-7, 1979. PMID: 104055.
248. Grossman B. The late recurrence of grade I transitional cell carcinoma of the ureter after conservative therapy. J Urol 120:251-252, 1978.
249. Grossman HB, Koff SA, Diokno AC. Cystometry in children. J Urol 117(5):646-8, 5/1977. PMID: 859205.

Book Chapters
1. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hemstreet III GP, Hautman SH, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Marberger M, Schalken JA, Messing E, Fradet Y, Droller MJ. Commettee 2. Cytology and tumor markers: tumor markers beyond cytology. In: Bladder Tumors. Soloway M, Carmack A, and Khoury S Health Publications Ltd: Paris, 65-138, 2006.

Last updated: 9/3/2009